Denali Therapeutics closes down 11% as 2025 operating expenses seen weighing
Hawkinsight
2025-03-01 09:07:33
2.14W
Zerbor
- Denali Therapeutics (NASDAQ:DNLI) closed down 11% Friday as investors seemed concerned about the biopharma's projected rise in operating expenses for 2025.
- In its Q4 and full-year 2024 financial results released after Thursday's closing bell, the company said it anticipated a 10%-15% increase
Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
